Calliditas Therapeutics AB(CALT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CALT Calliditas Therapeutics AB

未开盘 07-24 16:00:00 EDT

38.26

-0.24

-0.64%

盘后38.43

+0.17+0.46%

16:00 EDT

最高38.50	最低38.06	成交量2,207
今开38.50	昨收38.50	日振幅1.14%
总市值10.34亿	流通市值7.17亿	总股本2,702万
成交额8.47万	换手率0.01%	流通股本1,874万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CALT","market":"US","secType":"STK","nameCN":"Calliditas Therapeutics AB","latestPrice":38.255,"timestamp":1721851200000,"preClose":38.5,"halted":0,"volume":2207,"hourTrading":{"tag":"盘后","latestPrice":38.43,"preClose":38.255,"latestTime":"16:00 EDT","volume":2,"amount":76.86,"timestamp":1721851201730},"delay":0,"floatShares":18739000,"shares":27016723,"eps":-1.829049,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.245,"latestTime":"07-24 16:00:00 EDT","open":38.5,"high":38.5,"low":38.06,"amount":84738.616902,"amplitude":0.011429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.829049,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721894400000},"adr":0,"listingDate":1591329600000,"adjPreClose":38.5,"adrRate":2,"postHourTrading":{"tag":"盘后","latestPrice":38.43,"preClose":38.255,"latestTime":"16:00 EDT","volume":2,"amount":76.86,"timestamp":1721851201730},"volumeRatio":0.7832351702245772,"impliedVol":0.1487,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/CALT/wiki","defaultTab":"wiki","newsList":[{"id":"2440942071","title":"花旗：下调Calliditas Therapeutics(CALT.US)评级，由买入调整至中性评级, 目标价39.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2440942071","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440942071?lang=zh_cn&edition=full","pubTime":"2024-06-01 03:45","pubTimestamp":1717184740,"startTime":"0","endTime":"0","summary":"花旗：下调Calliditas Therapeutics(CALT.US)评级，由买入调整至中性评级, 目标价39.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406010345459f0c525c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406010345459f0c525c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","C","CALT"],"gpt_icon":0},{"id":"2439599650","title":"Calliditas Therapeutics AB：杰富瑞从买入中削减持股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2439599650","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439599650?lang=zh_cn&edition=full","pubTime":"2024-05-29 13:46","pubTimestamp":1716961583,"startTime":"0","endTime":"0","summary":"Calliditas Therapeutics AB：杰富瑞从买入中削减持股权","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405291346249efddeb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405291346249efddeb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JEF","AB","LU0029874061.USD","LU0128526141.USD","BK4135","BK4127","BK4007","BK4139","BK4590","CALT","LENZ"],"gpt_icon":0},{"id":"2439555354","title":"云顶新耀(01952)合作伙伴Calliditas(CALT.US)拟接受旭化成集团约11亿美元要约收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2439555354","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439555354?lang=zh_cn&edition=full","pubTime":"2024-05-29 07:59","pubTimestamp":1716940795,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀合作伙伴Calliditas Therapeutics AB宣布，旭化成集团提出以111.64亿瑞典克朗的价格收购Calliditas，作为其在医疗保健领域国际扩张计划的一部分。此要约收购比Calliditas于5月27日收盘价溢价约83%。2019年6月，云顶新耀与Calliditas签订独家授权许可协议，获得在大中华地区和新加坡开发以及商业化耐赋康的权利。要约收购完成后，云顶新耀也将与Calliditas及旭化成集团紧密合作，顺利完成衔接工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK1583","BK1161","01952","BK1574","CALT"],"gpt_icon":0},{"id":"2439530844","title":"Calliditas Therapeutics Ab2024财年第一财季实现净利润-23.68百万美元，同比减少31.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439530844","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439530844?lang=zh_cn&edition=full","pubTime":"2024-05-29 07:05","pubTimestamp":1716937541,"startTime":"0","endTime":"0","summary":"5月29日，Calliditas Therapeutics Ab公布财报，公告显示公司2024财年第一财季净利润为-23.68百万美元，同比减少31.85%；其中营业收入为28.42百万美元，同比增加55.05%，每股基本收益为-0.88美元。从资产负债表来看，Calliditas Therapeutics Ab总负债1.47亿美元，其中短期债务--，资产负债比为1.08，流动比率为0.03。机构评级：截至2024年5月29日，当前有9家机构对Calliditas Therapeutics Ab目标价做出预测，其中目标均价为39.12美元，其中最低目标价为29.56美元，最高目标价为49.94美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052907054395719175&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052907054395719175&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CALT"],"gpt_icon":0},{"id":"1136731785","title":"Calliditas盘前飙涨75%，获旭化成11亿美元要约收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1136731785","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1136731785?lang=zh_cn&edition=full","pubTime":"2024-05-28 19:56","pubTimestamp":1716897401,"startTime":"0","endTime":"0","summary":"此次收购溢价83%。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1127220.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["CALT"],"gpt_icon":1},{"id":"2437577998","title":"Calliditas Therapeutics AB：杰富瑞集团将目标价从57美元上调至58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437577998","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437577998?lang=zh_cn&edition=full","pubTime":"2024-05-24 12:55","pubTimestamp":1716526532,"startTime":"0","endTime":"0","summary":"Calliditas Therapeutics AB：杰富瑞集团将目标价从57美元上调至58美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405241255369556d32f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405241255369556d32f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT","LENZ","AB"],"gpt_icon":0},{"id":"2427634886","title":"Calliditas Therapeutics Ab盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427634886","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427634886?lang=zh_cn&edition=full","pubTime":"2024-04-16 00:31","pubTimestamp":1713198682,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日00时31分，Calliditas Therapeutics Ab股票出现波动，股价快速下跌5.26%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为0.27%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160031227a52e030&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160031227a52e030&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CALT","LENZ","BK4007"],"gpt_icon":0},{"id":"2426909884","title":"Calliditas Therapeutics Ab盘中异动 早盘股价大跌8.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426909884","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426909884?lang=zh_cn&edition=full","pubTime":"2024-04-10 21:41","pubTimestamp":1712756497,"startTime":"0","endTime":"0","summary":"北京时间2024年04月10日21时41分，Calliditas Therapeutics Ab股票出现异动，股价急速下跌8.12%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体跌幅为1.48%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410214137791fac4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410214137791fac4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","CALT"],"gpt_icon":0},{"id":"2426454031","title":"Calliditas Therapeutics Ab盘中异动 下午盘股价大涨6.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426454031","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426454031?lang=zh_cn&edition=full","pubTime":"2024-04-10 01:14","pubTimestamp":1712682841,"startTime":"0","endTime":"0","summary":"北京时间2024年04月10日01时14分，Calliditas Therapeutics Ab股票出现异动，股价急速上涨6.93%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体跌幅为0.55%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410011401875ae1fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410011401875ae1fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","CALT"],"gpt_icon":0},{"id":"2424839769","title":"Calliditas Therapeutics Ab盘中异动 早盘快速上涨5.81%报22.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424839769","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424839769?lang=zh_cn&edition=full","pubTime":"2024-04-04 21:31","pubTimestamp":1712237475,"startTime":"0","endTime":"0","summary":"北京时间2024年04月04日21时31分，Calliditas Therapeutics Ab股票出现波动，股价快速上涨5.81%。截至发稿，该股报22.48美元/股，成交量368股，换手率0.00%，振幅0.00%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为0.50%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240404213116791ecce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240404213116791ecce0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","CALT","BK4139"],"gpt_icon":0},{"id":"2420718205","title":"Calliditas Therapeutics Ab盘中异动 快速下跌7.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420718205","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420718205?lang=zh_cn&edition=full","pubTime":"2024-03-20 01:41","pubTimestamp":1710870065,"startTime":"0","endTime":"0","summary":"北京时间2024年03月20日01时41分，Calliditas Therapeutics Ab股票出现波动，股价大幅跳水7.17%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为0.03%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320014106791b7d62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320014106791b7d62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT","BK4007"],"gpt_icon":0},{"id":"2420408201","title":"Calliditas Therapeutics Ab盘中异动 早盘股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420408201","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420408201?lang=zh_cn&edition=full","pubTime":"2024-03-18 22:17","pubTimestamp":1710771468,"startTime":"0","endTime":"0","summary":"北京时间2024年03月18日22时17分，Calliditas Therapeutics Ab股票出现波动，股价快速下跌5.25%。截至发稿，该股报21.13美元/股，成交量4665股，换手率0.02%，振幅0.36%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为0.21%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。该公司的管道候选药物是 TARPEYO 药物，用于减少 IgA 肾病的蛋白尿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031822174987e79c79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031822174987e79c79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","BK4563","BK4139","IMRX","CALT"],"gpt_icon":0},{"id":"2419657975","title":"Calliditas Therapeutics Ab盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419657975","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419657975?lang=zh_cn&edition=full","pubTime":"2024-03-14 03:58","pubTimestamp":1710359884,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日03时58分，Calliditas Therapeutics Ab股票出现波动，股价快速拉升5.07%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体跌幅为0.49%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140358047a4c6160&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140358047a4c6160&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT","BK4007"],"gpt_icon":0},{"id":"2418328164","title":"云顶新耀合作伙伴Calliditas Therapeutics宣布美国FDA授予耐赋康®额外的七年孤儿药独占期","url":"https://stock-news.laohu8.com/highlight/detail?id=2418328164","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2418328164?lang=zh_cn&edition=full","pubTime":"2024-03-12 09:29","pubTimestamp":1710206940,"startTime":"0","endTime":"0","summary":"上海2024年3月12日 /美通社/ -- 云顶新耀的授权合作伙伴Calliditas Therapeutics AB宣布，基于耐赋康获得了新适应症的完全批准，美国食品药品监督管理局已授予其为期七年的额外孤儿药独占期至2030年12月。\" 韩国食品医药品安全部 于2022年11月授予 耐赋康孤儿药资格认定。2019年6月，云顶新耀与 Calliditas 签订独家授权许可协议，获得在大中华地区和新加坡开发以及商业化耐赋康的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4358690_ZH58690_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4006","01952","CMC","BK4007","BK1574","BK1583","BK1161","CALT"],"gpt_icon":0},{"id":"2417793153","title":"Calliditas Therapeutics Ab盘中异动 早盘快速拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417793153","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417793153?lang=zh_cn&edition=full","pubTime":"2024-03-07 23:09","pubTimestamp":1709824180,"startTime":"0","endTime":"0","summary":"北京时间2024年03月07日23时09分，Calliditas Therapeutics Ab股票出现波动，股价大幅上涨5.21%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为2.54%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240307230940861dc4ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240307230940861dc4ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CALT"],"gpt_icon":0},{"id":"2417297535","title":"Calliditas Therapeutics Ab盘中异动 大幅上涨13.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417297535","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417297535?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:32","pubTimestamp":1709735557,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日22时32分，Calliditas Therapeutics Ab股票出现波动，股价急速上涨13.42%。截至发稿，该股报23.20美元/股，成交量4983股，换手率0.02%，振幅0.00%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体跌幅为0.06%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240306223237875a866d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240306223237875a866d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT","BK4007"],"gpt_icon":0},{"id":"2414437802","title":"Calliditas Therapeutics Ab盘中异动 大幅上涨5.09%报21.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414437802","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414437802?lang=zh_cn&edition=full","pubTime":"2024-02-27 23:54","pubTimestamp":1709049281,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日23时54分，Calliditas Therapeutics Ab股票出现异动，股价急速拉升5.09%。截至发稿，该股报21.77美元/股，成交量3530股，换手率0.01%，振幅2.41%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体跌幅为0.36%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022723544187e73a45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022723544187e73a45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CALT"],"gpt_icon":0},{"id":"2414836597","title":"Calliditas Therapeutics Ab盘中异动 股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414836597","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414836597?lang=zh_cn&edition=full","pubTime":"2024-02-26 23:18","pubTimestamp":1708960694,"startTime":"0","endTime":"0","summary":"北京时间2024年02月26日23时18分，Calliditas Therapeutics Ab股票出现波动，股价大幅上涨5.14%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为0.03%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240226231815861d86b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240226231815861d86b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT","BK4007"],"gpt_icon":0},{"id":"2413950217","title":"Calliditas Therapeutics Ab2023财年实现净利润-43.91百万美元，同比减少7.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413950217","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413950217?lang=zh_cn&edition=full","pubTime":"2024-02-24 00:23","pubTimestamp":1708705395,"startTime":"0","endTime":"0","summary":"12月31日，Calliditas Therapeutics Ab公布财报，公告显示公司2023财年净利润为-43.91百万美元，同比减少7.78%；其中营业收入为1.14亿美元，同比增加43.69%，每股基本收益为-1.64美元。从资产负债表来看，Calliditas Therapeutics Ab总负债1.51亿美元，其中短期债务--，资产负债比为1.22，流动比率为0.04。机构评级：截至2023年12月31日，当前有8家机构对Calliditas Therapeutics Ab目标价做出预测，其中目标均价为47.16美元，其中最低目标价为17.00美元，最高目标价为57.79美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022400231781aef7da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022400231781aef7da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CALT"],"gpt_icon":0},{"id":"2413229830","title":"Calliditas Therapeutics Ab盘中异动 快速上涨7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413229830","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413229830?lang=zh_cn&edition=full","pubTime":"2024-02-23 04:38","pubTimestamp":1708634288,"startTime":"0","endTime":"0","summary":"北京时间2024年02月23日04时38分，Calliditas Therapeutics Ab股票出现波动，股价大幅上涨7.88%。Calliditas Therapeutics Ab股票所在的生物技术行业中，整体涨幅为2.12%。Calliditas Therapeutics Ab公司简介：Calliditas Therapeutics AB 是一家商业阶段的生物制药公司，专注于识别、开发和商业化孤儿适应症的新疗法，最初专注于医疗需求未得到满足的肾脏和肝脏疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402230438087913913d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402230438087913913d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CALT"],"gpt_icon":0}],"profile":{"websiteUrl":"https://www.calliditas.se/en","stockEarnings":[{"period":"1week","weight":-0.0151},{"period":"1month","weight":-0.03},{"period":"3month","weight":0.9668},{"period":"6month","weight":0.6908},{"period":"1year","weight":1.2087},{"period":"ytd","weight":0.486}],"compareEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.075},{"period":"6month","weight":0.1104},{"period":"1year","weight":0.1884},{"period":"ytd","weight":0.1387}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Calliditas Therapeutics AB 成立于2004年。 该公司是一家临床阶段的生物制药公司，致力于识别，开发和商业化孤儿适应症的新疗法，最初的重点是医疗需求未得到满足的肾脏和肝脏疾病。 他们的主要候选药物Nefecon是布地奈德的一种新颖的专有口服制剂，布地奈德是一种已建立的，有效的局部免疫抑制剂，用于治疗自身免疫性肾脏疾病IgA肾病或IgAN，其对医学的需求很高， 没有批准的治疗方法。 IgAN是一种进行性慢性疾病，久而久之会导致患者肾功能恶化，其中许多人最终有发展为终末期肾病或ESRD的风险，需要透析或进行肾脏移植。 Nefecon目前是IgAN研发中唯一有望改变疾病的候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.087252},{"month":2,"riseRate":0.25,"avgChangeRate":-0.026141},{"month":3,"riseRate":0.25,"avgChangeRate":0.057957},{"month":4,"riseRate":0.25,"avgChangeRate":-0.058711},{"month":5,"riseRate":0.5,"avgChangeRate":0.236302},{"month":6,"riseRate":0,"avgChangeRate":-0.025299},{"month":7,"riseRate":0.4,"avgChangeRate":0.049131},{"month":8,"riseRate":0,"avgChangeRate":-0.074678},{"month":9,"riseRate":0.5,"avgChangeRate":-0.042157},{"month":10,"riseRate":0,"avgChangeRate":-0.099382},{"month":11,"riseRate":1,"avgChangeRate":0.245246},{"month":12,"riseRate":0.5,"avgChangeRate":0.170781}],"exchange":"NASDAQ","name":"Calliditas Therapeutics AB","nameEN":"Calliditas Therapeutics AB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Calliditas Therapeutics AB(CALT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Calliditas Therapeutics AB(CALT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Calliditas Therapeutics AB,CALT,Calliditas Therapeutics AB股票,Calliditas Therapeutics AB股票老虎,Calliditas Therapeutics AB股票老虎国际,Calliditas Therapeutics AB行情,Calliditas Therapeutics AB股票行情,Calliditas Therapeutics AB股价,Calliditas Therapeutics AB股市,Calliditas Therapeutics AB股票价格,Calliditas Therapeutics AB股票交易,Calliditas Therapeutics AB股票购买,Calliditas Therapeutics AB股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Calliditas Therapeutics AB(CALT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Calliditas Therapeutics AB(CALT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}